Literature DB >> 27104806

Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.

Yao-Yun Fan1, Lindsay B Avery1, Mengmeng Wang1, Denise M O'Hara1, Sheldon Leung1, Hendrik Neubert1.   

Abstract

The neonatal Fc receptor (FcRn) is a homeostatic receptor responsible for prolonging immunoglobulin G (IgG) half-life by protecting it from lysosomal degradation and recycling it to systemic circulation. Tissue-specific FcRn expression is a critical parameter in physiologically-based pharmacokinetic (PBPK) modeling for translational pharmacokinetics of Fc-containing biotherapeutics. Using online peptide immuno-affinity chromatography coupled with high resolution mass spectrometry, we established a quantitative FcRn tissue protein expression profile in human FcRn (hFcRn) transgenic mice, Tg32 homozygous and hemizygous strains. The concentration of hFcRn across 14 tissues ranged from 3.5 to 111.2 pmole per gram of tissue. Our hFcRn quantification data from Tg32 mice will enable a more refined PBPK model to improve the accuracy of human PK predictions for Fc-containing biotherapeutics.

Entities:  

Keywords:  Antibody; IA-LC-HRMS; PBPK models; Tg32; human FcRn; tissue-based target quantification; transgenic mice

Mesh:

Substances:

Year:  2016        PMID: 27104806      PMCID: PMC4968098          DOI: 10.1080/19420862.2016.1178436

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  39 in total

1.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

Review 2.  Tissue sample preparation in bioanalytical assays.

Authors:  Kerri M Smith; Yan Xu
Journal:  Bioanalysis       Date:  2012-03       Impact factor: 2.681

Review 3.  Antibody-drug conjugates: current status and future directions.

Authors:  Heidi L Perez; Pina M Cardarelli; Shrikant Deshpande; Sanjeev Gangwar; Gretchen M Schroeder; Gregory D Vite; Robert M Borzilleri
Journal:  Drug Discov Today       Date:  2013-11-15       Impact factor: 7.851

Review 4.  Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.

Authors:  H M Jones; Y Chen; C Gibson; T Heimbach; N Parrott; S A Peters; J Snoeys; V V Upreti; M Zheng; S D Hall
Journal:  Clin Pharmacol Ther       Date:  2015-01-09       Impact factor: 6.875

5.  Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities.

Authors:  Susan H Tam; Stephen G McCarthy; Kerry Brosnan; Kenneth M Goldberg; Bernard J Scallon
Journal:  MAbs       Date:  2013-04-02       Impact factor: 5.857

6.  The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs.

Authors:  Derry C Roopenian; Gregory J Christianson; Thomas J Sproule; Aaron C Brown; Shreeram Akilesh; Nadja Jung; Stefka Petkova; Lia Avanessian; Eun Young Choi; Daniel J Shaffer; Peter A Eden; Clark L Anderson
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

7.  Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

Authors:  Takuo Suzuki; Akiko Ishii-Watabe; Minoru Tada; Tetsu Kobayashi; Toshie Kanayasu-Toyoda; Toru Kawanishi; Teruhide Yamaguchi
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

8.  Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy.

Authors:  Lanyan Fang; Duxin Sun
Journal:  Drug Metab Dispos       Date:  2008-03-20       Impact factor: 3.922

Review 9.  Albumin as a versatile platform for drug half-life extension.

Authors:  Darrell Sleep; Jason Cameron; Leslie R Evans
Journal:  Biochim Biophys Acta       Date:  2013-04-29

Review 10.  Pharmacokinetic models for FcRn-mediated IgG disposition.

Authors:  Jim J Xiao
Journal:  J Biomed Biotechnol       Date:  2012-05-14
View more
  12 in total

1.  Distribution of FcRn Across Species and Tissues.

Authors:  Sari Latvala; Bjoern Jacobsen; Michael B Otteneder; Annika Herrmann; Sven Kronenberg
Journal:  J Histochem Cytochem       Date:  2017-04-12       Impact factor: 2.479

2.  The neonatal Fc receptor is a pan-echovirus receptor.

Authors:  Stefanie Morosky; Alexandra I Wells; Kathryn Lemon; Azia S Evans; Sandra Schamus; Christopher J Bakkenist; Carolyn B Coyne
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-11       Impact factor: 11.205

3.  Quantification of IgG monoclonal antibody clearance in tissues.

Authors:  Miro J Eigenmann; Ludivine Fronton; Hans Peter Grimm; Michael B Otteneder; Ben-Fillippo Krippendorff
Journal:  MAbs       Date:  2017-06-14       Impact factor: 5.857

4.  Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans.

Authors:  Armin Sepp; Mats Bergström; Marie Davies
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

5.  Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.

Authors:  Wolfgang F Richter; Gregory J Christianson; Nicolas Frances; Hans Peter Grimm; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2018-05-09       Impact factor: 5.857

6.  Quantification of Neonatal Fc Receptor and Beta-2 Microglobulin in Human Liver Tissues by Ultraperformance Liquid Chromatography-Multiple Reaction Monitoring-based Targeted Quantitative Proteomics for Applications in Biotherapeutic Physiologically-based Pharmacokinetic Models.

Authors:  Xiazi Qiu; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2020-07-28       Impact factor: 3.922

7.  Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.

Authors:  Armin Sepp; Guy Meno-Tetang; Andrew Weber; Andrew Sanderson; Oliver Schon; Alienor Berges
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-11       Impact factor: 2.745

Review 8.  Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.

Authors:  Patrick M Glassman; Joseph P Balthasar
Journal:  Drug Metab Pharmacokinet       Date:  2018-11-22       Impact factor: 3.614

9.  FcRn Expression in Wildtype Mice, Transgenic Mice, and in Human Tissues.

Authors:  Tommy Li; Joseph P Balthasar
Journal:  Biomolecules       Date:  2018-10-15

Review 10.  The Neonatal Fc Receptor (FcRn): A Misnomer?

Authors:  Michal Pyzik; Kine M K Sand; Jonathan J Hubbard; Jan Terje Andersen; Inger Sandlie; Richard S Blumberg
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.